Losers At Healthcare: Synageva BioPharma (NASDAQ:GEVA), Auspex Pharmaceuticals (NASDAQ:ASPX), ImmunoGen (NASDAQ:IMGN), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)



Synageva BioPharma Corp (NASDAQ:GEVA) last released its earnings data on Friday, May 2nd. The company reported ($1.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($1.19) by $0.03. Analysts expect that Synageva BioPharma Corp will post $-5.90 EPS for the current fiscal year. Synageva BioPharma Corp (NASDAQ:GEVA)stock performance was 5.87% in last session and finished the day at $ 85.40. Traded volume was 206,033 shares in the last session and the average volume of the stock remained 323,619 shares. The beta of the stock remained 0.6. Synageva BioPharma Corp (NASDAQ:GEVA) insider ownership is 0.10%

Auspex Pharmaceuticals Inc (NASDAQ:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced that the Company was added to the Russell 2000® Index (as well as the larger Russell 3000®Index) at the close of market on March 31, 2014 as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes. Auspex Pharmaceuticals Inc (NASDAQ:ASPX) rose 10.88% to $ 18.92 Friday on volume of 371,284 shares. The intra-day range of the stock was $ 18.38 – 21.36. Auspex Pharmaceuticals Inc (NASDAQ:ASPX)has a market capitalization of $ 446.70 million.

Immunogen (NASDAQ:IMGN) issued its quarterly earnings data on Friday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by $0.17, Analyst Ratings Network reports. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $13.28 million. ImmunoGen, Inc. (NASDAQ:IMGN)’s stock on May 2, 2014 reported a increase 5.26% to the closing price of $ 12.06. Its fifty two weeks range is $ 11.78 – 20.25. The total market capitalization recorded $ 1.03 billion. The overall volume in the last trading session was 1,024,641 shares. In its share capital, ImmunoGen, Inc.(NASDAQ:IMGN) has 85.81 million outstanding shares.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.68) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.87) by $0.19. On average, analysts expect Infinity Pharmaceuticals to post $-3.31 EPS for the current fiscal year and $-2.80 EPS for the next fiscal year. On Friday, shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI)Advanced 5.66% to close the day at $ 9.16. Company’s monthly performance is recorded as -18.94%. Infinity Pharmaceuticals Inc. (NASDAQ:INFI)quarterly revenue growth is -28.72%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone